Can I Sell Medical Devices Through Cross-Border E-Commerce to China?

Date:

Share post:

Can I Sell Medical Devices Through Cross-Border E-Commerce to China?

The short answer is yes—but only for a narrow range of low-risk devices, and the rules are changing fast. As of 2025, fewer than 50 specific medical device types are explicitly permitted under China’s Cross-Border E-Commerce Retail Import Positive List (跨境电商零售进口正面清单, kuàjìng diànshāng língshòu jìnkǒu zhèngmiàn qīngdān). Over 80% of medical device imports attempted via cross-border e-commerce (CBEC) are seized or returned at customs due to non-compliance, costing foreign firms an average of CNY 85,000 per rejected shipment. The total CBEC medical device market in China reached approximately CNY 12 billion in 2024, growing 15% year-on-year, but the window for unregistered devices is narrowing. This FAQ breaks down exactly what you can and cannot sell, the regulatory traps to avoid, and the real costs of getting it wrong.

What the Law Says: The Positive List and Its Limits

China’s CBEC retail import regime operates on a strict “positive list” model. Only products explicitly listed in the Cross-Border E-Commerce Retail Import Positive List can be imported through B2C or B2B2C channels without full standard registration. The list is maintained by the Ministry of Commerce (MOFCOM), the General Administration of Customs (GACC), and the National Medical Products Administration (NMPA).

For medical devices, the list is severely restricted. Most Class II and Class III devices—those with moderate to high risk—are excluded. The few devices that are allowed must also comply with NMPA labeling and safety standards, even though they bypass the full registration process.

Key rule: If your device touches the body (e.g., wearable monitor, glucose test strip), it is likely regulated by NMPA and not eligible for CBEC unless explicitly listed. The positive list is updated approximately every 2–3 years, but the trend is toward tightening, not loosening.

Chinese term: The National Medical Products Administration (国家药品监督管理局, NMPA, guójiā yàopǐn jiāndū guǎnlǐ jú). Every medical device sold in China—via CBEC or traditional import—must meet NMPA technical standards, even if registration is not required for CBEC.

Which Medical Devices Are Actually Allowed?

As of the 2025 update, the following device categories are conditionally permitted under the CBEC positive list:

  • Blood pressure monitors (electronic, non-invasive)
  • Clinical electronic thermometers
  • Digital pulse oximeters (finger-clip type)
  • First-aid kits (basic, non-invasive contents only)
  • Insulin pen needles (single-use, sterile, Class II but listed)
  • Contact lenses and lens care solutions (Class III, subject to special quota)

All other devices—including surgical instruments, implants, ventilators, infusion pumps, catheters, diagnostic reagents, and most wearable sensors—are prohibited from CBEC import. Even for listed devices, there are quantity limits per transaction (usually 1–2 units per order) and an annual per-person cap of CNY 26,000 across all CBEC purchases.

Device Category NMPA Class Allowed via CBEC? Special Conditions
Digital blood pressure monitor Class II Yes ≤ 2 units per order; must have Chinese labeling
Clinical thermometer (electronic) Class I Yes No mercury allowed
Finger pulse oximeter Class II Yes Must meet GB/T 9706.1 safety standard
Contact lenses Class III Limited Quota-based; foreign supplier must have Chinese legal rep
Surgical mask Class II No Must use general trade with NMPA registration
HbA1c test kit Class II/III No Classified as in-vitro diagnostic (IVD); registration required
Insulin pump Class III No Prohibited; must use hospital procurement channel
First-aid kit (basic) Class I Yes No surgical instruments or medications inside

The Hidden Challenge: NMPA Registration vs. CBEC Simplicity

Many foreign sellers assume that because CBEC offers a “fast lane” for consumer goods, medical devices enjoy the same simplified process. This is a costly mistake. Even if your device is on the positive list, you must still demonstrate compliance with NMPA technical standards—including GB (national standard) and YY (medical device industry standard) requirements.

For example, a blood pressure monitor sold via CBEC must still pass electromagnetic compatibility testing (YY 0505), clinical accuracy validation (YY 0670), and labeling requirements in Chinese. This testing costs an average of CNY 120,000–200,000 per device variant and takes 3–5 months. If your device fails testing, you cannot sell it through any channel—CBEC or otherwise—until corrected.

The second hidden challenge is after-sales liability. Under CBEC rules, the foreign seller is the official “importer of record” and bears full responsibility for product safety, adverse events, and recalls. Chinese customs and the NMPA can hold the foreign company liable for injuries caused by a CBEC-sold device. In 2024, three foreign firms faced total fines exceeding CNY 6 million for selling unregistered devices via CBEC that resulted in patient harm.

Decision Framework: If your device appears on the positive list and is Class I or low-risk Class II, CBEC may work as a test channel while you prepare full NMPA registration. If your device is Class II (medium risk) or Class III (high risk), choose the conventional general trade + NMPA registration route—it costs more upfront (CNY 300,000–1,500,000) but avoids seizure and liability risks.

Three Critical Pitfalls When Selling Medical Devices Via CBEC to China

Pitfall 1: Misclassifying your device as a “health consumer product” rather than a medical device. Cost: Customs seizure + fines of CNY 50,000–200,000 + loss of goods (average CNY 85,000 per shipment). Fix: Request a formal classification opinion from the NMPA Medical Device Standards Administration (国家级医疗器械标准管理中心) before listing. The cost of classification review is approximately CNY 15,000–30,000 and takes 20–30 business days.
Pitfall 2: Assuming CBEC exempts you from Chinese labeling and instruction requirements. Cost: Customs detention for 90+ days + storage fees of CNY 50 per pallet per day + mandatory relabeling (average CNY 45,000). Fix: Prepare Chinese-language labeling that follows NMPA Order 6 (《医疗器械说明书和标签管理规定》) before shipping. Include device name, model, intended use, warnings, manufacturer name and address, production date, and shelf life—all in simplified Chinese.
Pitfall 3: Ignoring the requirement for a local after-sales service agent. Cost: NMPA administrative penalty (CNY 20,000–100,000) + suspension of CBEC listing for 12 months. Fix: Appoint a Chinese legal entity as your after-sales service provider before listing on any CBEC platform (Tmall Global, JD Global, Kaola). The agent must hold a valid Medical Device Operation License (医疗器械经营许可证, yīliáo qìxiè jīngyíng xǔkě zhèng) for your device class.

Alternative Routes: Beyond CBEC for Medical Devices

If your device is prohibited from CBEC—and most are—your options include:

  1. General trade import + NMPA registration. The standard route for Class II and III devices. Requires a Chinese legal entity (WFOE or joint venture) to hold the registration certificate (注册证, zhùcè zhèng). Timeline: 12–24 months. Cost: CNY 300,000–1,500,000 per device.
  2. Free Trade Zone (FTZ) bonded import. Devices can be stored in a bonded warehouse at a pilot FTZ (Shanghai, Tianjin, Guangzhou, etc.) and sold to hospitals or distributors without full customs clearance until the end customer is confirmed. Useful for low-volume, high-value devices. Timeline: 2–4 months.
  3. Medical device distributor partnership. Instead of selling directly to consumers, license your device to a Chinese distributor who holds NMPA registration and has existing hospital or pharmacy channels. Revenue share typically 20–30%.
  4. Hospital clinical trial pathway. If your device is novel and not yet approved, you can import it under a clinical trial exemption for use in registered hospitals. Very limited volume (usually <500 units).

For most foreign medical device companies, CBEC is a minor side channel at best. The real market—hospitals, clinics, pharmacies—requires full NMPA registration and a physical Chinese presence. The CBEC route is best seen as a test-and-learn channel for low-risk consumer devices or as a bridge while full registration is underway.

Next Steps: How to Move Forward

Based on the analysis above, here are three concrete actions you can take right now:

  1. Verify your device’s classification and positive list eligibility. Cross-check your device against the latest Cross-Border E-Commerce Retail Import Positive List (updated January 2025) and NMPA’s Medical Device Classification Catalog. If you are unsure how to classify your product, read our NMPA Medical Device Classification Guide for step-by-step instructions and a self-assessment checklist.
  2. Prepare for NMPA testing and registration. Even if CBEC seems viable, we recommend starting the NMPA registration process in parallel. Our Complete NMPA Registration Process Guide covers documentation, testing timelines, and cost breakdowns for Class I, II, and III devices. Early preparation can save 6–12 months vs. starting after a CBEC pilot.
  3. Assess whether a WFOE or distributor partnership is better for your strategy. If your device requires full NMPA registration, you will need a Chinese legal entity. Compare the pros and cons of a wholly foreign-owned enterprise (外商独资企业, WFOE, wàishāng dúzī qǐyè) versus a distributor partnership in our WFOE vs. Distributor: Which Model Is Right for Your Medical Device? analysis.

— China Gateway 360 —
Remote China market entry support, built around execution.

Related articles

Trademark Update: Pilot Zone Expansion — Key Takeaways

Trademark Pilot Zone Expansion: Fast-Track Registration Now Available in 38 Cities The China National Intellectual Property Administration (CNIPA) has

Trademark Update: Foreign Investment Rule Revision — Key Takeaways

Trademark Update: Foreign Investment Rule Revision — Key Takeaways The April 2025 revision to China's Foreign Investment Law (外商投资法, Foreign Investmen

Trademark Update: Tax Incentive Changes — Key Takeaways

Trademark Update: Tax Incentive Changes — Key Takeaways China’s State Taxation Administration (STA) has revised its tax incentive framework for tradem

Trademark Update: Market Opening Announcement — Key Takeaways

China Trademark Market Opening: Key Takeaways from 2025 Policy Updates On February 20, 2025, China’s National Intellectual Property Administration (CN